

IND SAFETY REPORT: INITIAL WRITTEN REPORT

TO: Division of Biologic Oncology Products, Center for Drug Evaluation and Research, FDA
Division of Drug Oncology Products, Center for Drug Evaluation and Research, FDA

FAX: 301-796-9849

301-796-9845

1. IND NUMBER

59699

7921

2. AGENT NAME

BMS 247550 (ixabepilone, Ixempra)

Bevacizumab (rhuMab VEGF)

3. DATE

June 25, 2009

4. SPONSOR

Division of Cancer Treatment and Diagnosis, National Cancer Institute

5. REPORTER=S NAME, TITLE, AND INSTITUTION

L. Austin Doyle , MD-Senior Investigator for Investigational Therapeutics 2, Investigational Drug Branch, CTEP, DCTD, NCI

Helen Chen, MD-Associate Branch Chief for Investigational Therapeutics 3, Investigational Drug Branch, CTEP, DCTD, NCI

6. PHONE NUMBER

301-496-1196

7. FAX NUMBER

301-402-0428

8. PROTOCOL NUMBER (AE #)

CALGB-40502 (AE # 1839475)

9. PATIENT IDENTIFICATION

115520

10. AGE

69

11. SEX

Female

12. DESCRIPTION OF ADVERSE EVENT

The patient is a 69-year-old female with invasive breast carcinoma who experienced a grade 3 seizure while on a phase 3 study using the investigational agents bevacizumab and ixabepilone. She began her first course of treatment on April 27, 2009, and received her first and only dose of bevacizumab on April 27, 2009, (Cycle 1, Day 1) and the last dose of ixabepilone on May 4, 2009 (Cycle 1, Day 8). The patient presented to the emergency room on May 7, 2009 (Cycle 1, Day 11), after having a generalized tonic-clonic seizure. A CT scan of the head and brain without contrast was negative. A portable chest x-ray revealed a 5 cm mass within the left middle lung. On May 8, 2009 (Cycle 1, Day 12), an MRI of the brain with and without contrast was negative for abnormal enhancements or masses. The patient had a neurology consult and was started on Keppra. The patient did not have any seizure activity during hospitalization and was discharged to home on May 9, 2009 (Cycle 1, Day 13). Additional information has been requested from the investigational site. There is a reasonable possibility that the adverse event may have been caused by the drug.

13. DOSE, ROUTE, AND SCHEDULE

Ixabepilone 16 mg/m² IV over 1 hour on Days 1, 8, and 15

Bevacizumab 10 mg/kg IV over 30-90 min on Days 1 and 15

14. DATES OF TREATMENT

The patient began the investigational therapy on April 27, 2009, and received the last dose of bevacizumab on April 27, 2009 (Cycle 1, Day 1) and the last dose of ixabepilone on May 4, 2009 (Cycle 1, Day 8).

15. ACCRUAL AND IND EXPERIENCE

The number of patients enrolled in NCI-sponsored clinical trials using bevacizumab = 21442 and the number of patients enrolled in NCI-sponsored clinical trials using ixabepilone is 1785. There have been 47 seizure incidences reported to the NCI through AdEERS as serious adverse events for bevacizumab and 5 seizure incidences reported to the NCI through AdEERS as serious adverse events for ixabepilone

16. COMMENTS

AT THIS TIME, NO OTHER INFORMATION IS AVAILABLE. IF UPON FURTHER INVESTIGATION RELEVANT INFORMATION BECOMES AVAILABLE, THEN A FOLLOW-UP REPORT WILL BE SUBMITTED IN ACCORDANCE WITH 21CFR 312.32(D)(2).

DISCLAIMER per 21 CFR 312.32(e): THIS SAFETY REPORT DOES NOT NECESSARILY REFLECT A CONCLUSION OR ADMISSION BY THE CTEP IDB SENIOR INVESTIGATOR/SPONSOR THAT THE INVESTIGATIONAL AGENT/THERAPY CAUSED OR CONTRIBUTED TO THE ADVERSE EXPERIENCE BEING REPORTED.

0002